# Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct05522491/  
OnCo record `nct05522491` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of olaparib in triple-negative breast cancer, run by Hebei Medical University Fourth Hospital, not yet recruiting.

## Summary

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer is a phase 2, interventional study registered as NCT05522491 by Hebei Medical University Fourth Hospital, with a registry enrolment figure of 30 participants, started 2026-09-01 and due to reach its primary completion in 2030-09-01. Interventions recorded: Olaparib. Conditions listed: Solid Tumor. Triple-negative eligibility wording from the registry: "Histologically confirmed recurrent and metastatic TNBC patients without BRCA1/2 mutation and BRCA1 promoter methylation". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05522491
- Phase: 2
- Setting: An Open-label, Single-arm, Single-center Exploratory Clinical Study of Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
- Sponsor: Hebei Medical University Fourth Hospital
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05522491: https://clinicaltrials.gov/study/NCT05522491

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05522491.json